<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267887</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00016728</org_study_id>
    <secondary_id>NCI-2020-00598</secondary_id>
    <secondary_id>STUDY00016728</secondary_id>
    <nct_id>NCT04267887</nct_id>
  </id_info>
  <brief_title>Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer</brief_title>
  <official_title>Advanced ChemoHormonal Therapy for Treatment Na√Øve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well the combination of apalutamide, abiraterone acetate, and&#xD;
      prednisone after chemotherapy work in treating patients that have received no prior treatment&#xD;
      (treatment naive) for high risk prostate cancer that is sensitive to androgen deprivation&#xD;
      therapy (castration sensitive) and has spread to other parts of the body (metastatic). This&#xD;
      study also aims to understand the inheritance of prostate cancer. If a gene or genes that&#xD;
      cause prostate cancer can be found, the diagnosis and treatment of prostate cancer may be&#xD;
      improved. Testosterone (a male hormone) can cause the growth of prostate cancer cells.&#xD;
      Hormone therapy using apalutamide may fight prostate cancer by blocking the use of&#xD;
      testosterone by the tumor cells. Antihormone therapy, such as abiraterone acetate, may lessen&#xD;
      the amount of testosterone made by the body. Anti-inflammatory drugs such as prednisone lower&#xD;
      the body's immune response and are used with other drugs in the treatment of some types of&#xD;
      cancer. Apalutamide, abiraterone acetate, and prednisone after chemotherapy may work better&#xD;
      in treating patients with castration sensitive prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Efficacy of apalutamide in combination with abiraterone acetate + prednisone following&#xD;
      docetaxel with ongoing androgen deprivation therapy in men with high risk metastatic&#xD;
      castration sensitive disease.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Safety and tolerability of apalutamide in combination with abiraterone acetate +&#xD;
      prednisone following docetaxel with ongoing androgen deprivation therapy.&#xD;
&#xD;
      II. Time to event.&#xD;
&#xD;
      III. Depth of prostate specific antigen (PSA) response.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Quality of life.&#xD;
&#xD;
      II. Falls.&#xD;
&#xD;
      III. Molecular changes from prostate cancer over time.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive apalutamide orally (PO) once daily (QD), abiraterone acetate PO QD, and&#xD;
      prednisone PO QD. Cycles repeat every 4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients also receive androgen deprivation therapy per standard of&#xD;
      care.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for up to 10&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete prostate specific antigen (PSA) response</measure>
    <time_frame>At 12 months from the start of treatment</time_frame>
    <description>The complete PSA response is defined as a PSA =&lt; 0.2 ng/ml, confirmed with a 2nd measurement at least 3 weeks later. The estimated PSA response rate will be computed with 95% exact confidence interval. Binomial exact test will be used to determine whether the complete PSA response rate is significantly greater than 43%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From day 1 of treatment, assessed up to 10 years</time_frame>
    <description>Overall survival will be assessed with each patient visit. After the subject is off active follow up, survival will be assessed by phone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events &gt;= grade 2</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with PSA response &gt;= 50% decrease</measure>
    <time_frame>From baseline, assessed up to 12 months</time_frame>
    <description>The proportion will be reported with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with PSA response &gt;= 90% decrease</measure>
    <time_frame>From baseline, assessed up to 12 months</time_frame>
    <description>The proportion will be reported with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From start of treatment, assessed up to 10 years</time_frame>
    <description>Kaplan-Meier plot will be used to describe the survival distributions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to biochemical (PSA) progression</measure>
    <time_frame>From start of treatment, assessed up to 10 years</time_frame>
    <description>Kaplan-Meier plot will be used to describe the survival distributions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiographic progression</measure>
    <time_frame>From start of treatment, assessed up to 10 years</time_frame>
    <description>Kaplan-Meier plot will be used to describe the survival distributions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptomatic progressive disease</measure>
    <time_frame>From start of treatment, assessed up to 10 years</time_frame>
    <description>Kaplan-Meier plot will be used to describe the survival distributions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next therapy for metastatic castration resistant prostate cancer</measure>
    <time_frame>From start of treatment, assessed up to 10 years</time_frame>
    <description>Kaplan-Meier plot will be used to describe the survival distributions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Castration-Sensitive Prostate Carcinoma</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer AJCC v8</condition>
  <condition>Stage IVA Prostate Cancer AJCC v8</condition>
  <condition>Stage IVB Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (apalutamide, abiraterone acetate, prednisone, ADT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive androgen deprivation therapy per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (apalutamide, abiraterone acetate, prednisone, ADT)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Yonsa</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiandrogen Therapy</intervention_name>
    <description>Given ADT per standard of care</description>
    <arm_group_label>Treatment (apalutamide, abiraterone acetate, prednisone, ADT)</arm_group_label>
    <other_name>ADT</other_name>
    <other_name>Androgen Deprivation Therapy</other_name>
    <other_name>Androgen Deprivation Therapy (ADT)</other_name>
    <other_name>Anti-androgen Therapy</other_name>
    <other_name>Anti-androgen Treatment</other_name>
    <other_name>Antiandrogen Treatment</other_name>
    <other_name>Hormone Deprivation Therapy</other_name>
    <other_name>Hormone-Deprivation Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (apalutamide, abiraterone acetate, prednisone, ADT)</arm_group_label>
    <other_name>ARN 509</other_name>
    <other_name>ARN-509</other_name>
    <other_name>ARN509</other_name>
    <other_name>Erleada</other_name>
    <other_name>JNJ 56021927</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (apalutamide, abiraterone acetate, prednisone, ADT)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (apalutamide, abiraterone acetate, prednisone, ADT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (apalutamide, abiraterone acetate, prednisone, ADT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed prostate cancer OR a&#xD;
             strong suspicion of prostate cancer as evidenced by metastatic disease in a pattern&#xD;
             consistent with prostate cancer (such as blastic lesions on a nuclear medicine bone&#xD;
             scan or lymphadenopathy on the computed tomography [CT] scan) AND a PSA &gt; 50 ng/mL&#xD;
&#xD;
          -  High risk disease (defined as meeting 2 of the 3: (1) visceral metastatic disease, (2)&#xD;
             3 or more bone lesions, (3) Gleason 8-10) at the time diagnosed metastatic&#xD;
&#xD;
          -  If a patient has received androgen deprivation therapy (ADT) for neoadjuvant or&#xD;
             adjuvant therapy at least 24 months MUST have elapsed since its use to day 1 of&#xD;
             restarting ADT for metastatic castration sensitive disease&#xD;
&#xD;
          -  ADT sensitive disease- no evidence of rising PSA or new metastatic deposits since&#xD;
             starting ADT&#xD;
&#xD;
          -  Have completed up to 6 cycles of docetaxel since developing metastatic castration&#xD;
             sensitive disease with no more than 12 weeks elapsed since day 21 of the final cycle&#xD;
&#xD;
          -  All races and ethnic groups will be included&#xD;
&#xD;
          -  Life expectancy of greater than 18 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL, independent of transfusion and/or growth factors&#xD;
&#xD;
          -  Leukocytes &gt; 3,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000 x 10^9/uL, independent of transfusion and/or growth factors&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (Note: In subjects with Gilbert's&#xD;
             syndrome, if total bilirubin is &gt; 1.5 x ULN, measure direct and indirect bilirubin and&#xD;
             if direct bilirubin is =&lt; 1.5 x ULN, subject may be eligible)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) &lt;&#xD;
             2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Albumin &gt; 3 g/dL&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &gt; 30 mL/min/1.73 m^2; per Modification of&#xD;
             Diet in Renal Disease (MDRD) calculation or institutional standard&#xD;
&#xD;
          -  Potassium &gt;= 3.5 mmol/L&#xD;
&#xD;
          -  Medications known to lower the seizure threshold must be discontinued or substituted&#xD;
             at least 4 weeks prior to day 1 of study&#xD;
&#xD;
          -  Agrees to use a condom (even men with vasectomies) and another effective method of&#xD;
             birth control if he is having sex with a woman of childbearing potential or agrees to&#xD;
             use a condom if he is having sex with a woman who is pregnant while on study drug and&#xD;
             for 3 months following the last dose of study drug. Must also agree not to donate&#xD;
             sperm during the study and for 3 months after receiving the last dose of study drug&#xD;
&#xD;
          -  Ability to understand, and the willingness to sign, a written informed consent&#xD;
             document, as well as comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are unwilling to stop taking saw palmetto, PC-SPECs or other herbal&#xD;
             agents known to affect the PSA&#xD;
&#xD;
          -  Patients may not have received any other investigational agents within 30 days prior&#xD;
             to day 1 of study&#xD;
&#xD;
          -  Prior exposure to apalutamide, enzalutamide, abiraterone acetate, darolutamide, or any&#xD;
             other second-generation antiandrogen therapy&#xD;
&#xD;
               -  Note: prior exposure to bicalutamide, flutamide, nilutamide, or any other&#xD;
                  first-generation androgen receptor antagonist is permitted. No washout is&#xD;
                  required. Subjects may be on one of these at the time of consent, but it must be&#xD;
                  stopped prior to day 1 of study treatment. These drugs are frequently used in the&#xD;
                  newly diagnosed metastatic setting to blunt the effect of the testosterone spike&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to apalutamide or other agents used in the study&#xD;
&#xD;
          -  Subject has another active malignancy other than non-melanomatous skin cancer (unless&#xD;
             it is metastatic) or superficial bladder cancer&#xD;
&#xD;
          -  Either of the following:&#xD;
&#xD;
               -  Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke&#xD;
                  within 1 year, brain arteriovenous malformation, Schwannoma, meningioma, or other&#xD;
                  benign central nervous system [CNS] or meningeal disease which may require&#xD;
                  treatment with surgery or radiation therapy)&#xD;
&#xD;
               -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart&#xD;
                  failure or left ventricular ejection fraction &lt; 50%, arterial or venous&#xD;
                  thromboembolic events (e.g. pulmonary embolism, cerebrovascular accident&#xD;
                  including transient ischemic attacks), or clinically significant ventricular&#xD;
                  arrhythmias within 6 months prior to day 1 of study&#xD;
&#xD;
          -  Current evidence of any of the following:&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Gastrointestinal disorder affecting absorption&#xD;
&#xD;
               -  Active infection (e.g. human immunodeficiency virus [HIV] or viral hepatitis)&#xD;
&#xD;
               -  Any chronic medical condition requiring a higher dose of corticosteroid than a&#xD;
                  total of 10 mg prednisone/prednisolone daily&#xD;
&#xD;
               -  Any condition that in the opinion of the investigator, would preclude&#xD;
                  participation in this study.&#xD;
&#xD;
               -  Avoid concomitant strong CYP3A4 inducers during abiraterone acetate treatment. If&#xD;
                  a strong CYP3A4 inducer must be co-administered, increase the abiraterone acetate&#xD;
                  dosing frequency to twice a day only during the co-administration period (e.g.,&#xD;
                  from 1,000 mg once daily to 1,000 mg twice a day).&#xD;
&#xD;
               -  Avoid co-administration of abiraterone acetate with CYP2D6 substrates that have a&#xD;
                  narrow therapeutic index. If an alternative treatment cannot be used, exercise&#xD;
                  caution and consider a dose reduction of the concomitant CYP2D6 substrate&#xD;
&#xD;
               -  Baseline moderate and severe hepatic impairment (Child Pugh Class B &amp; C)&#xD;
&#xD;
          -  Inability to stop a prohibited medication:&#xD;
&#xD;
               -  Atypical antipsychotics (e.g. clozapine, olanzapine, risperidone, ziprasidone)&#xD;
&#xD;
               -  Bupropion&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Meperidine and pethidine&#xD;
&#xD;
               -  Phenothiazine antipsychotics (e.g. chlorpromazine, mesoridazine, thioridazine)&#xD;
&#xD;
               -  Tricyclic antidepressants (e.g. amitriptyline, desipramine, doxepin, imipramine,&#xD;
                  maprotiline, mirtazapine&#xD;
&#xD;
               -  Tramadol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie N Graff</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Bailey</last_name>
      <phone>503-418-9104</phone>
      <email>bailesh@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Julie N. Graff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Julie Graff</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Androgen Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

